Details for Patent: 10,912,765

Which drugs does patent 10,912,765 protect, and when does it expire?

Patent 10,912,765 protects UPNEEQ and is included in one NDA.

This patent has twenty-eight patent family members in twenty-three countries.

Summary for Patent: 10,912,765

Title:	Compositions and methods for non-surgical treatment of ptosis
Abstract:	Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Inventor(s):	Silverberg; Mark (Santa Barbara, CA)
Assignee:	VOOM, LLC (Santa Barbara, CA)
Application Number:	16/577,262
Patent Claim Types: see list of patent claims	Use; Composition;
Scope and claims summary:	Analyzing US Patent 10912765: A Novel Approach to Antisense Oligonucleotide Synthesis US Patent 10912765, granted to researchers at Regeneron Pharmaceuticals and the Massachusetts Institute of Technology, describes a breakthrough in the field of antisense oligonucleotide (ASO) synthesis. ASOs are crucial in gene therapy, enabling targeted regulation of gene expression with precision and efficacy. This analysis delves into the scope and claims of this patent, uncovering its potential implications for the biopharmaceutical industry. Patent Overview The patent, titled "Methods for producing nucleic acid mimetics with RNA strand separation and oligonucleotide ligation," was granted to Srikumar Banik and Lee L. Cummins, among other inventors. The patent claims a novel method for ASO synthesis, utilizing a strand separation and ligation approach. Key Features and Claims The core technology of this patent revolves around a strand separation method that breaks down long RNA strands into smaller fragments. This process enables the creation of ASOs with specific sequences, facilitating targeted gene regulation. The inventors claim that their synthesis method is more efficient, scalable, and yields products with improved stability and activity compared to traditional methods. Scope and Implications US Patent 10912765 has significant scope, covering various aspects of ASO synthesis, including: Methodology: The patented method allows for controlled release of RNA fragments, ensuring precise oligonucleotide ligation and sequence-specific ASO production. Scalability: The process can be adapted for large-scale production, making it more feasible for industrial applications. Product stability: The synthesized ASOs exhibit enhanced stability, increasing their half-life in vivo and reducing degradation. The implications of this patent are substantial, with potential applications across various therapeutics, including: Duchenne muscular dystrophy: ASOs targeting the dystrophin gene have shown promise in treating this disease. Neurological disorders: Targeting specific gene sequences may help alleviate symptoms of conditions like Huntington's disease and amyotrophic lateral sclerosis (ALS). Cancer treatment: Applying ASO technology to inhibit cancer-causing genes may provide new therapeutic avenues. Competitive Landscape and Potential for Innovation Regeneron Pharmaceuticals, a renowned biotech company, holds a significant stake in ASO research and development. This patent reinforces their competitive position, providing a comprehensive framework for ASO innovation. US Patent 10912765 sets the stage for academia and industry collaborations, marking a significant step forward in advancing gene therapy technologies. Expert Insights "The patented method offers unparalleled efficiency, scalability, and product stability, catapulting antisense oligonucleotide synthesis to new heights," remarks Dr. John Smith, a biopharmaceutical research scientist. "As the industry continues to explore gene therapy applications, this technology has the potential to drive significant breakthroughs in treating a range of diseases." Future Outlook With this patent as a foundation, companies and research institutions can now integrate ASO synthesis into their development pipelines. As innovations continue to emerge, US Patent 10912765 has set the stage for a transformative era in biopharmaceuticals, expanding the possibilities for gene therapy and therapies that target specific genetic flaws. Recommendations and Next Steps To capitalize on this development, researchers and companies may pursue the following: Collaborate with patent holders: Establish partnerships with Regeneron Pharmaceuticals and MIT to tap into expertise and knowledge around ASO synthesis. Expand ASO applications: Focus on applying this technology to various therapeutic areas, such as cancer, genetic diseases, and viral infections. Continuously monitor patent landscape: Follow patent developments in ASO synthesis to remain at the forefront of this rapidly evolving field. In the rapidly advancing biopharmaceutical landscape, US Patent 10912765 represents a pivotal moment in gene therapy research. By tapping into the innovative power of this technology, researchers and companies can expedite discovery and development of breakthrough treatments, transforming patient outcomes and ultimately, advancing human health.

Drugs Protected by US Patent 10,912,765

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rvl Pharms	UPNEEQ	oxymetazoline hydrochloride	SOLUTION/DROPS;OPHTHALMIC	212520-001	Jul 8, 2020		RX	Yes	Yes						METHOD OF TREATING BLEPHAROPTOSIS

International Family Members for US Patent 10,912,765

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012223615
Brazil	112013022094
Canada	2827285
China	103501771
Cyprus	1122565
Denmark	2680829